Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 9949.78
GNMSF's Cash to Debt is ranked higher than
57% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. GNMSF: 9949.78 )
Ranked among companies with meaningful Cash to Debt only.
GNMSF' s 10-Year Cash to Debt Range
Min: 10.54  Med: 484.87 Max: N/A
Current: 9949.78
Equity to Asset 0.82
GNMSF's Equity to Asset is ranked higher than
68% of the 594 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. GNMSF: 0.82 )
Ranked among companies with meaningful Equity to Asset only.
GNMSF' s 10-Year Equity to Asset Range
Min: 0.21  Med: 0.43 Max: 0.82
Current: 0.82
0.21
0.82
F-Score: 6
Z-Score: 39.42
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 48.13
GNMSF's Operating margin (%) is ranked higher than
96% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. GNMSF: 48.13 )
Ranked among companies with meaningful Operating margin (%) only.
GNMSF' s 10-Year Operating margin (%) Range
Min: -434.42  Med: -49.34 Max: 10760.13
Current: 48.13
-434.42
10760.13
Net-margin (%) 59.16
GNMSF's Net-margin (%) is ranked higher than
96% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. GNMSF: 59.16 )
Ranked among companies with meaningful Net-margin (%) only.
GNMSF' s 10-Year Net-margin (%) Range
Min: -10124.65  Med: -154.67 Max: 35.43
Current: 59.16
-10124.65
35.43
ROE (%) 20.86
GNMSF's ROE (%) is ranked higher than
92% of the 761 Companies
in the Global Biotechnology industry.

( Industry Median: -29.50 vs. GNMSF: 20.86 )
Ranked among companies with meaningful ROE (%) only.
GNMSF' s 10-Year ROE (%) Range
Min: -112.03  Med: -33.19 Max: 22.38
Current: 20.86
-112.03
22.38
ROA (%) 14.60
GNMSF's ROA (%) is ranked higher than
93% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -25.57 vs. GNMSF: 14.60 )
Ranked among companies with meaningful ROA (%) only.
GNMSF' s 10-Year ROA (%) Range
Min: -36.89  Med: -27.17 Max: 13.1
Current: 14.6
-36.89
13.1
ROC (Joel Greenblatt) (%) 1425.31
GNMSF's ROC (Joel Greenblatt) (%) is ranked higher than
99% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -333.14 vs. GNMSF: 1425.31 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
GNMSF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -675.71  Med: -31.43 Max: 1097
Current: 1425.31
-675.71
1097
Revenue Growth (3Y)(%) 23.90
GNMSF's Revenue Growth (3Y)(%) is ranked higher than
80% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. GNMSF: 23.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
GNMSF' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: 3.85 Max: 331.5
Current: 23.9
0
331.5
» GNMSF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with GNMSF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 94.10
GNMSF's P/E(ttm) is ranked lower than
77% of the 215 Companies
in the Global Biotechnology industry.

( Industry Median: 41.60 vs. GNMSF: 94.10 )
Ranked among companies with meaningful P/E(ttm) only.
GNMSF' s 10-Year P/E(ttm) Range
Min: 42.72  Med: 83.33 Max: 112.63
Current: 94.1
42.72
112.63
PE(NRI) 94.10
GNMSF's PE(NRI) is ranked lower than
77% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 39.20 vs. GNMSF: 94.10 )
Ranked among companies with meaningful PE(NRI) only.
GNMSF' s 10-Year PE(NRI) Range
Min: 42.64  Med: 83.33 Max: 181.04
Current: 94.1
42.64
181.04
P/B 15.11
GNMSF's P/B is ranked lower than
87% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. GNMSF: 15.11 )
Ranked among companies with meaningful P/B only.
GNMSF' s 10-Year P/B Range
Min: 1.63  Med: 6.87 Max: 25.05
Current: 15.11
1.63
25.05
P/S 54.04
GNMSF's P/S is ranked lower than
80% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 11.60 vs. GNMSF: 54.04 )
Ranked among companies with meaningful P/S only.
GNMSF' s 10-Year P/S Range
Min: 3.08  Med: 9.41 Max: 54.77
Current: 54.04
3.08
54.77
PFCF 8406.25
GNMSF's PFCF is ranked lower than
100% of the 144 Companies
in the Global Biotechnology industry.

( Industry Median: 45.01 vs. GNMSF: 8406.25 )
Ranked among companies with meaningful PFCF only.
GNMSF' s 10-Year PFCF Range
Min: 3.77  Med: 57.43 Max: 8543.75
Current: 8406.25
3.77
8543.75
POCF 388.73
GNMSF's POCF is ranked lower than
94% of the 203 Companies
in the Global Biotechnology industry.

( Industry Median: 35.83 vs. GNMSF: 388.73 )
Ranked among companies with meaningful POCF only.
GNMSF' s 10-Year POCF Range
Min: 3.67  Med: 51.68 Max: 395.09
Current: 388.73
3.67
395.09
EV-to-EBIT 107.64
GNMSF's EV-to-EBIT is ranked lower than
83% of the 224 Companies
in the Global Biotechnology industry.

( Industry Median: 32.56 vs. GNMSF: 107.64 )
Ranked among companies with meaningful EV-to-EBIT only.
GNMSF' s 10-Year EV-to-EBIT Range
Min: -390.4  Med: -4.80 Max: 1407.3
Current: 107.64
-390.4
1407.3
Current Ratio 5.18
GNMSF's Current Ratio is ranked higher than
55% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. GNMSF: 5.18 )
Ranked among companies with meaningful Current Ratio only.
GNMSF' s 10-Year Current Ratio Range
Min: 1.3  Med: 1.83 Max: 5.18
Current: 5.18
1.3
5.18
Quick Ratio 5.18
GNMSF's Quick Ratio is ranked higher than
57% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. GNMSF: 5.18 )
Ranked among companies with meaningful Quick Ratio only.
GNMSF' s 10-Year Quick Ratio Range
Min: 1.3  Med: 1.83 Max: 5.18
Current: 5.18
1.3
5.18

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) (%) 0.90
GNMSF's Earnings Yield (Greenblatt) (%) is ranked higher than
77% of the 813 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. GNMSF: 0.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
GNMSF' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.1  Med: 1.20 Max: 456.1
Current: 0.9
0.1
456.1

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:GEN.Denmark, 0MGB.UK,
Genmab A/S is a biotechnology company that utilizes antibody products. The Company's treatments focus on cancer and other serious illnesses. The Company has a pipeline of drugs in various stages of development and approval. The Company has licensed rights to HuMAb-Mouse, a transgenic mouse technology designed by Medarex. The platform produces high affinity human antibodies. Using the technology also circumvents the need for humanization or genetic engineering which can often drag out drug development. The Company also uses its proprietary UniBody platform. UniBody also binds to one site and produces no immune response. HuMax-CD38 is a drug in development for the treatment of multiple myeloma. The Company also has treatments for asthma (R1671 and R4930), peripheral vascular disease (R1512), hepatitis C (HuMax-HepC), organ transplant rejection (HuMax-TAC), cancer (HuMax-CD32b), and oncology (HuMax-TF). The Company has a myriad of other products in development, pending completion and approval. The Company owns its own manufacturing facilities. Within the facilities, it has the capabilities of producing multiple antibody products simultaneously.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK